scholarly journals Subclinical Cushing's Disease Accompanied by Malignant Hypertension and Diabetes Mellitus.

2002 ◽  
Vol 41 (7) ◽  
pp. 566-570 ◽  
Author(s):  
Takashi NAGAI ◽  
Makoto IMAMURA ◽  
Shuuzou MISUMI ◽  
Masatomo MORI
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Yuki Yamauchi ◽  
Hiraku Kameda ◽  
Kazuno Omori ◽  
Michio Tani ◽  
Kyu Yong Cho ◽  
...  

Abstract Background Subclinical Cushing’s disease (SCD) is defined by corticotroph adenoma-induced mild hypercortisolism without typical physical features of Cushing’s disease. Infection is an important complication associated with mortality in Cushing’s disease, while no reports on infection in SCD are available. To make clinicians aware of the risk of infection in SCD, we report a case of SCD with disseminated herpes zoster (DHZ) with the mortal outcome. Case presentation An 83-year-old Japanese woman was diagnosed with SCD, treated with cabergoline in the outpatient. She was hospitalized for acute pyelonephritis, and her fever gradually resolved with antibiotics. However, herpes zoster appeared on her chest, and the eruptions rapidly spread over the body. She suddenly went into cardiopulmonary arrest and died. Autopsy demonstrated adrenocorticotropic hormone-positive pituitary adenoma, renal abscess, and DHZ. Conclusions As immunosuppression caused by SCD may be one of the triggers of severe infection, the patients with SCD should be assessed not only for the metabolic but also for the immunodeficient status.


2002 ◽  
pp. 67-74 ◽  
Author(s):  
U Feldt-Rasmussen ◽  
R Abs ◽  
BA Bengtsson ◽  
H Bennmarker ◽  
M Bramnert ◽  
...  

OBJECTIVE: To compare baseline characteristics in adult patients with growth hormone (GH) deficiency (GHD) who had previously been treated for Cushing's disease or acromegaly with data from patients with GHD of other aetiologies. To study the effects of GH therapy in those patients who had completed at least 6 months of GH replacement. DESIGN: Data from a large outcomes research database (KIMS (Pharmacia International Metabolic Database)). METHODS: 135 patients were identified with previous Cushing's disease, 40 had had acromegaly, and 1392 had GHD of other aetiologies. The number of additional hormone deficiencies, and the mean age of the patients were similar in the three groups. Similar proportions of patients in each group were treated using surgery, but radiotherapy was used more often in patients with acromegaly than those with other diagnoses. RESULTS: At baseline, the prevalence of diabetes mellitus and hypertension were significantly higher in the group treated for Cushing's disease, and the prevalence of stroke was significantly higher in the group treated for acromegaly. The incidence of coronary heart disease and claudication were similar in all three groups. Patients treated for Cushing's disease had lower bone mineral density and suffered fractures more often than other GHD adults. Body mass index, waist-hip ratio, serum concentrations of lipids and standard deviation scores of serum concentrations of insulin-like-growth factor-I were similar in the three groups. The dose of GH administered was comparable in the three groups and the effects of GH replacement on waist circumference, blood pressure and quality of life were also similar across the groups. The numbers and types of adverse events reported were not different between the groups. CONCLUSIONS: These data suggest that the characteristics of patients in these diagnostic groups depend on the primary disease which resulted in GHD, and that the clinical expression of GHD does not differ between the groups. Patients with previous hypercortisolism showed more long-term effects of their disease, such as diabetes mellitus, hypertension and fractures. A benefit from GH replacement was evident in patients previously treated for acromegaly and Cushing's disease particularly in relation to quality of life.


2010 ◽  
Vol 72 (3) ◽  
pp. 343-348 ◽  
Author(s):  
Hirokazu ISHINO ◽  
Yasushi HARA ◽  
Takahiro TESHIMA ◽  
Shigeki TANAKA ◽  
Susumu TAKEKOSHI ◽  
...  

2019 ◽  
Author(s):  
Dimitra Tampouratzi ◽  
Styliani Kalaitzidou ◽  
Georgios Papadakis ◽  
Chrysi Karavasili ◽  
Michalis Kotis ◽  
...  

2011 ◽  
Vol 96 (3) ◽  
pp. 632-642 ◽  
Author(s):  
R. N. Clayton ◽  
D. Raskauskiene ◽  
R. C. Reulen ◽  
P. W. Jones

Context: Pituitary ACTH-dependent Cushing's disease (CD) is uncommon, and there are very limited data on long-term mortality. Objective: The aim was to summarize what is known about mortality in ACTH-dependent CD, to report on our own data, and to provide a meta-analysis of six other reports that addressed mortality of CD. Design and Methods: Vital status of 60 CD patients was recorded as of December 31, 2009, and the standardized mortality ratio (SMR) was calculated and compared with the general population of England and Wales, United Kingdom. A meta-analysis of SMRs from seven studies (including ours) was performed for overall mortality in CD. Where reported (four studies), a similar meta-analysis was performed for those patients whose hypercortisolism was in remission after treatment compared to those patients from the same center with persistent disease. Results: 1. From Stoke-on-Trent, 51 of 60 patients were female, median age at diagnosis was in the range of 36–46 yr, and median follow-up was 15 yr. There were 13 deaths, nine due to cardiovascular disease. Overall SMR for the whole cohort was 4.8 (95% confidence interval, 2.8–8.3) (P < 0001). SMR for vascular disease was 13.8 (7.2–36.5) (P < 0001). For persistent disease (n = 6), SMR was 16 (6.7–38.4) vs. remission (n = 54) SMR of 3.3 (1.7–6.7); after adjustment for age and sex, relative risk of death for persistent disease was 10.7 (2.3–48.6) (P = 0.002). Hypertension and diabetes mellitus were associated with significantly worse survival. 2. Using a random effects model meta-analysis revealed an overall (remission plus persistent disease) SMR of 2.2 (1.45–3.41) (P < 0.001). Pooled SMR was 1.2 (0.45–3.2) (P = not significant) for patients in remission and 5.5 (2.7–11.3) (P = 0.001) for patients with persistent disease. Persistence of disease, older age at diagnosis, and presence of hypertension and diabetes are the main determinants of mortality. Conclusions: Overall mortality in CD is double that of the general population. However, patients with CD in remission fare much better than those with persistence of hypercortisolism, and they appear not to have an increased mortality rate. Hypertension and diabetes mellitus are risk factors for worse outcome. Because diagnosis and treatment of patients are at a young age, much longer follow-up of patients in remission is required before one can be confident that their mortality outcome is no different from that of the general population, especially because cardiovascular risk factors may persist after successful biochemical control of the disease.


2011 ◽  
Vol 34 (9) ◽  
pp. 731-732 ◽  
Author(s):  
C. Fiorentino ◽  
C. Motta ◽  
D. T. Wolosinska ◽  
S. Monti ◽  
F. Mori ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document